Summertime dosage-dependent hypersensitivity to an angiotensin II receptor blocker by unknown








Background: Summertime dips in blood pressure (BP), both in normotensive and hypertensive subjects, are well 
known. However, the dips are small and are not related to particular forms or doses of antihypertensive medica-
tion. Nevertheless it is the practice in some quarters to decrease antihypertensive medication in summer, and/or to 
increase in winter. Large scale studies being inconclusive, there are calls for long-term examination of the relationship 
between environmental temperature and blood pressure in single individuals under medication.
Case presentation: While analyzing data from a subject whose BP had been controlled for a decade with the 
angiotensin-II receptor blocker losartan, an extreme, dosage-dependent, summertime dip came to light. Downward 
dosage adjustment appeared essential and may have prevented hypotension-related pathology.
Conclusion: The benefits of aggressive medication (the “J curve” phenomenon) being debated, the possibility of 
seasonal hypersensitivity, perhaps explicable in terms of differential signaling by countervailing receptors, should be 
taken into account when considering dosage adjustments in hypertensive subjects.
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Background
Conflicting opinions on seasonal dosage adjustment
Small summertime declines in blood pressure (e.g. 
5–10  mm  Hg) have long been known, both in normo-
tensive and hypertensive subjects. Indeed, adverse car-
diovascular events being more frequent in winter, it is 
the practice in some quarters to decrease antihyperten-
sive medication in summer, and/or increase in winter 
[1]. But this is controversial. Ambulatory blood pressure 
(ABP) recordings often reveal a small dip in BP values 
when subjects are resting at night [2]. In Italy, Modesti 
et al. reported in 2006 [3] that in summer this night-time 
dipping was less evident, and systolic values (SBPs) were 
slightly increased; it was only with day-time BP meas-
urements that a summer decrease was evident. They 
cautioned against reducing dosage of antihypertensive 
medication in hot weather. On the other hand, based on 
clinic BP measurements of 500,000 subjects drawn from 
ten climatically diverse regions of China, in 2012 Lew-
ington et al. [4] affirmed that “higher doses or additional 
drug(s) may be required in winter to achieve the same 
blood pressure control as at other times of the year”. In 
other words, they advised lowering dosage in summer-
time. Indeed, in 2013 Modesti came to agree that “it is 
possible that heat-exposed subjects need lower dosages… 
because of lower BP in warm conditions” [5].
However, seasonal influences on responses to specific 
antihypertensive medications are not well documented. 
Apart from logistic considerations (e.g. patient confi-
dentiality), this may be due the relative newness of some 
medications, so that long-term studies are not yet avail-
able. In Japan, Hozawa et  al. [6] relied on the home BP 
measurements of volunteers, but had no information 
on medications. In Scotland, Aubinière-Robb et  al. [7] 
relied on clinic measurements of treated hypertensive 
subjects, but had “incomplete prescribing data”. Further-
more, their location implied more concern for potential 
adverse effects of increases in BP in cold weather, than of 
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decreases in BP in hot weather. The subtropical island of 
Taiwan has temperatures closer to those in summer-time 
Ontario, but the winter-summer variation is much less. 
For Taiwan, Tu et al. [8] reported no influence of season 
on the response to antihypertensive medication, but type 
and dosage were unspecified.
The most definitive study to date is the above noted 
work of Lewington et  al. [4]. The percentage differences 
between summer and winter did not differ between those 
on antihypertensive medication (type unspecified), and 
those who were not. However, absolute differences were 
greater in hypertensive subjects (differences averaging 
11.0 versus 9.6  mm Hg). Floras has recently cautioned 
that when marginal hypertension is diagnosed in sum-
mer-time, initiating therapeutic dosages may be subopti-
mum, but the possibility of extreme seasonal variation in 
sensitivity to medication was not entertained [9].
Calls for long‑term single patient studies
Despite many studies, seasonal variations in BP are not 
clearly related to particular forms or dosages of medica-
tion in individual subjects. It is recognized that “patients 
are exposed to antihypertensive treatment for decades; 
yet, long-term safety of these drugs is not well-reported. 
Most prospective randomised trials end after a few years 
without long-term follow up” [10]. Indeed, in 2013 Mod-
esti et  al. [11] declared that some of the limitations of 
their approach “would be addressed in future studies 
based on repeated measurements according to a longi-
tudinal design and focusing on the assessment of tem-
perature and BP changes within a single individual”. This 
need for long-term single-individual studies was echoed 
in 2012 by Cuspidi et  al. [12], and in 2013 by Tomlin-
son et al. [13], who called for “carefully designed studies 
using individual level patient data to examine this issue in 
more depth”. To some extent, the present study meets this 
requirement, but regrettably with the absence of night 
readings. In 2011 Handler [14] reported a case where the 
subject, based on home BP readings and postural hypo-
tension, had opted to stop medication in summer, but 
there were few details. In 2013 Chen et al. [15] reported a 
3 year follow-up of hypertensives treated with the angio-
tensin converting enzyme (ACE) inhibitor (benazepril); 
average seasonal fluctuations were of the same order as 
reported by Lewington et  al. [4]. It was concluded that 
“patients should monitor and treat blood pressure more 
carefully in cold days”.
J‑curve phenomenon
Seasonal BP variations are not seen as related to the so-
called “J curve” phenomenon [16]. While the benefits of 
decreasing blood pressure are clear, there comes a point 
below which there are negative consequences, marked 
by a J-like inflection on plots of adverse cardiovascular 
events against BP. Such consequences include acute kid-
ney injury, now becoming more evident among those 
on medication [13]. Indeed, it is held that its “important 
implications for clinical practice should make investiga-
tion on the J-curve phenomenon a priority for cardiovas-
cular medicine” [16].
While analyzing data from a subject whose BP had 
been controlled for a decade with the angiotensin-II 
receptor blocker (ARB) losartan, an extreme, potentially 
dangerous, summer-time influence came to light [17]. 
ARBs being treatment of choice for millions of subjects, 
it is unlikely this is an isolated case.
Case presentation
Materials and methods
In August 1999, mild hypertension (circa 150/90 mm Hg) 
was found during routine examination of a 60  year old 
biomedical researcher. In the 1960s he had been briefly 
involved in hypertension researcha. When studying the 
activation of cultured human lymphocytes in the 1980s 
he discovered a gene (RGS-2) [18] that was later found 
to regulate BP [19, 20]. With appreciation of possible 
immunological aspects of hypertension [21], he followed 
the course of his new condition with deep professional 
interest. This led to his carrying out all readings for, and 
authoring, the present report. Beginning in January 2000, 
resting BP readings were taken at least once daily (usually 
both in early morning and late evening) by the subject at 
his home. The continuing accuracy of his Omron digi-
tal BP monitor (model HEM-712C) was ascertained by 
comparing with readings from his mercury sphygmoma-
nometer, with those obtained in his physician’s officeb 
and, in 2015, by comparing with a new Omron monitor 
(HEM-7121C).
Since Ontario Climate Centre records of daily tempera-
tures for the subject’s lakeside city (Kingston, Ontario) 
did not become available until 2008, values for a loca-
tion 24  km north (Hartington) were employed. The lat-
ter tends to be 2–3° cooler/hotter in winter/summer than 
Kingston. In the period of this study, indoor tempera-
tures were regulated at around 22°C during cold weather. 
In summer months fans were employed and only short 
periods were spent in air-conditioned environments.
Throughout the study period standard blood and 
urine tests remained within normal ranges, except that 
on occasions creatinine levels approached high normal. 
The subject’s resting pulse had registered around 50/
min for many years. His lifestyle was that of an academic 
workaholic—several hours a day at a computer inter-
rupted by frequent brisk walks, and twice weekly runs 
(2 km). Height and weight had remained relatively con-
stant throughout adult life (currently 1.76  m and 72  kg; 
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BMI =  23.2). The hypertension was assumed to be pri-
mary (‘essential’), and was not further investigated. How-
ever, at an early stage antihypertensive medication was 
associated with postural hypotension and an instance of 
acute renal colic. These encouraged close home BP moni-
toring with dosage adjustment by the subject targeting 
130/80  mm  Hg. While the present report is primarily 
concerned with a 12 year period when losartan was the 
sole medication (2003–2014), the stage will be set with a 
brief account of an initial 3 year exploratory period with 
various other medications.
The period 2000–2002
In the year 2000, two one-month trials (Feb., Apr.) of daily 
losartan (25  mg) with chlorothiazide (12.5  mg) resulted 
in progressive falls in day-time BP, with some systolic val-
ues (SBP) around 100 mm Hg (Figure 1). Consistent with 
this, the subject experienced some dizziness on standing 
up abruptly. On cessation of these medications, BP values 
progressively returned to previous levels.
In June, chlorothiazide alone (12.5 mg) had little effect. 
However, losartan alone (25  mg), taken at the height of 
summer (August, with environmental temperatures 
approaching 30°C), produced a progressive and more 
profound fall in pressure, with SBP values again below 
100  mm Hg, and diastolic (DPB) values approaching 
60  mm  Hg. Shortly after cessation of therapy there was 
acute renal colic and blood pressure rose abruptly (Fig-
ure  1). A ureteral stone observed on X-rays was pre-
sumed to have passed in the urine.
In view of the timing, and the subject not having pre-
viously experienced renal colic, it was considered likely 
that stone formation had been facilitated by hypotension. 
Indeed, there is now increasing awareness that acute kid-
ney injury (AKI) can follow ARB medication in a range 
of settings, particularly during acute hypovolemic ill-
ness [13]. Medications were avoided for the next 2 years 
and pressure values remained relatively constant in 
the 150/90 range. In the summer of 2001 there was the 
expected small BP dip, which correlated inversely with 
environmental temperature (Figure 2).
In the summer of 2002 mild hypertension was con-
firmed by one session of 24  h ambulatory BP (ABP) 
monitoring and, for a 6  week period (beginning in the 
Figure 1 Daily variation in SBP (black circles) and DBP (grey circles) over a 3 year period, as related to (1) maximum daily environmental tempera-
tures (small black squares) and (2) periodic treatments at constant dosage with losartan (red triangles), chlorothiazide (green triangles) or ramipril 
(blue triangles). At bottom right, the two rows of red triangles mark the initiation of a 12 year period (2003–2014) where the day-to-day dosage of 
losartan was varied. Renal colic in the year 2000 is marked by a large red triangle. At that time home BP measurements were usually taken 2–3 times 
a day—in the early morning, in the early afternoon, and in the evening. All measurements are directly plotted. Gaps indicate periods of travel when 
readings were discontinued. Since records of temperature values for the subject’s lakeside city (Kingston, Ontario) did not become available until 
2008, values for a location 24 km north (Hartington) were employed.
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last week of July), daily combination therapy with losar-
tan (25  mg) and chlorothiazide (12.5  mg) was resumed 
(Figure  1). Again, there were extreme declines in pres-
sure values and some minor dizzy episodes. BP was 
controlled more satisfactorily with the ACE inhibitor, 
ramipril (2.5  mg/day; late September to early Decem-
ber). However the subject experienced a persistent dry 
cough, so ramipril was discontinued. Although there 
had been some dry coughing with losartan, therapy with 
losartan alone was resumed at the end of December 2002 
(rows of red triangles at extreme right in Figure 1). Dos-
age was adjusted daily by the subject according to his BP 
readings. This proved satisfactory for the next 12  years, 
despite some dry coughing.
The period 2003–2014
With various combinations of half (12.5  mg) and whole 
(25  mg) tablets, daily losartan dosage was varied over 
the range, 0, 12.5, 25, 37.7 and 50 mg, taken either in the 
early morning or, from December 2010 onwards, split 
between mornings and evenings (under guidance of BP 
readings taken at the same times). Further fine adjust-
ment was attempted by trying to maintain regular dos-
age patterns—e.g. 12.5, 25, 12.5, 25 mg, etc. Apart from 
weekly sildenafil citrate (50 mg), which tended to lower 
BP, losartan was the sole medication.
For the first 4  years (2003–2006) the required aver-
age losartan dose was 16  mg/day, rising to 18  mg/day 
for the next 3  years (2007–2009). Thereafter, the aver-
age requirement rose from 19 mg/day (2010) to 44 mg/
day (2013) and 33  mg/day (2014). An example of the 
ability to fine-tune day-time BP readings over the 2003-
2009 period is shown for the year 2007 (Figure 3). With 
relatively constant losartan dosages (average 18 mg/day) 
blood pressure readings were maintained at acceptable 
values (130/80 mm Hg). There was generally no need for 
special dosage adjustments in the hot summer season.
These same BP values were sustained in the 2010–2014 
period. However, when, for some unknown reason, the 
total losartan requirement increased, an extreme down-
ward dosage adjustment became necessary in the sum-
mer season. This is shown for the year 2012 in Figure 4.
The detailed BP plot for 2011, when increased losartan 
dosage first became necessary, is of special interest (Fig-
ure  5). BP levels were maintained relatively constant by 
decreasing losartan dosage in the summer months and 
increasing dosage in the following winter. The sub-zero 
maximum daily temperatures early in the year were asso-
ciated with 25 mg/day dosages. The increase in losartan 
requirement to 50  mg/day began in the late fall when 
maximum temperatures were still above zero, so seeming 
to reflect an influence internal to the subject, as well as 
from the environment.
Monthly losartan requirements for the entire 12  year 
period are shown in Figure  6. At the doses employed 
between 2003 and 2009 (average 16–18 mg/day), usually 
no seasonal adjustment was needed. In 2006 (a particu-
larly hot year), only minor adjustment was needed. The 
plot for 2011 was distinctive. At first the requirement 
was high, but decreased to previous values during spring 
and summer. However, later in the year as environmen-
tal temperature declined, there was a sharp increase in 
losartan requirement. Subsequently (2012–2014), a sum-
mer requirement for extreme downward dosage adjust-
ment emerged.
Relationship between temperature and BP
Plots of BP and losartan dosage against temperature 
showed minimal influence of temperature during the 
2003–2009 period. Figure  7 shows data for 2007 (from 
Figure  3). The regression line for losartan dosage (red) 
was essentially horizontal. However, plots for the year 
2011 (Figure  8) showed a biphasic linear regression fit 
to losartan dosage. The ascending limb of the regression 
reflects the dosage increase from 25 mg/day in the cold 
early part of the year, to 50 mg/day in the less cold late 
part of the year. The descending limb of the regression 
reflects the decreasing requirement during the summer 
months.
Figure  9 shows regression plots for the entire 2003–
2014 period. The curves were essentially horizontal for 
Figure 2 Seasonal variation in SBP and DBP in absence of hyper-
tensive medication. Daily values for each month in the year 2001 are 
averaged and plotted with standard errors. Corresponding monthly 
average temperature values are shown without symbols (maximum, 
continuous red line; average, dashed black line; minimum, dotted blue 
line).
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2003–2009. Thus, dosage was independent of tempera-
ture. In 2010 came the first indication of the extreme sea-
sonal influence—explicit from 2012 onwards. Indeed, by 
extrapolation, under these conditions losartan could have 
been abandoned at around 34°C.
Discussion
The present study arose from the belief that an interfer-
ence with physiological homeostatic controls, which was 
deemed necessary for management of primary hyperten-
sion, would require close BP assessment—an assessment 
Figure 3 Daily variation in SBP and DBP in 2007, as related to (1) maximum daily environmental temperatures and (2) varying losartan dosage. 
Home BP measurements were usually twice daily—in the early morning and late evening—and these values were averaged for plotting. Least-
squares regression (sixth order) polynomial fits to the points are shown as continuous lines (the fit is third order for the black temperature line). For 
other details see Figure 1.
Figure 4 Daily variation in SBP and DBP in 2012, as related to (1) maximum daily environmental temperatures and (2) varying losartan dosage. For 
details see Figures 1, 3.
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which would be facilitated by the digital devices that had 
become available for home-monitoring. Whether it is 
the actual BP level, or variation in that level, that is most 
responsible for adverse clinical consequences, is much 
debated [9, 22]. Here, the day-to-day adjustment of losar-
tan dosage to observed daily BP levels would seem to 
address both factors.
Angiotensin II receptors
Antihypertensive, dosage-dependent, effects of losar-
tan were evident in early short-term studies with both 
Figure 5 Daily variation in SBP and DBP in 2011, as related to (1) maximum daily environmental temperatures and (2) varying losartan dosage. For 
details see Figures 1, 3.
Figure 6 Monthly losartan requirements for a 12 year period 
(2003–2014). 2003, black triangles; 2004, dark yellow triangles; 2005, 
green circles; 2006, black squares; 2007, blue diamonds; 2008, orange 
squares; 2009, grey triangles; 2010, red diamonds; 2011, cyan circles; 
2012, black circles; 2013, green diamonds; 2014, dark red circles. Data for 
2012–2014 include standard errors.
Figure 7 Daily values for SBP, DBP, and losartan dosages for the year 
2007, as a function of the corresponding maximum environmental 
temperatures. Least-squares regression fits (third order polynomial) to 
the points are shown as continuous lines (red for losartan dosage). This 
is a re-plot of the data of Figure 3.
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normal volunteers and patients [23]. Thus, Gottlieb et al. 
[24] noted in 1993 that vascular dilation and BP-lower-
ing effects were maximal with 25 mg/day and declined at 
higher doses, whereas effects deemed ‘neurohormonal,’ 
such as increased levels of renin and of the circulating 
angiotensin II octapeptide (Ang II), continued to increase 
at higher concentrations. With the present subject, sum-
mer losartan hypersensitivity became most evident when 
dosage increased from around 25 to 50 mg/day, consist-
ent with a neurohormonal influence.
Cell surface Ang II receptors (subtypes AT1R and 
AT2R) are present in various mammalian species. It is the 
reaction of Ang II with AT1R, the dominant high-affinity 
receptor, that is blocked with high specificity by losartan 
[25]. Independently of losartan, the reaction normally 
triggers Gq-protein signalling that mobilises intracel-
lular Ca++, resulting in increased vascular tone. Such 
signalling is itself susceptible to modulation by regula-
tory factors—such as Regulator of G-Protein Signaling-2 
(RGS-2) [18–20]—which are themselves subject to regu-
latory inputs. So determining how seasonal factors feed 
into this system, and whether the key seasonal factor is, 
indeed, temperature [11, 26], are unlikely to be easy.
Although bound to plasma albumin, losartan itself is 
rapidly degraded to a longer-lived, pharmacologically 
more potent, carboxylic acid derivative, also bound to 
albumin; this sustains AT1R blockade non-competitively 
for many hours [27, 28]. Thus, provided a sufficient dose 
is employed, and the period between doses is not too 
long, successive losartan doses may act cumulatively. This 
is consistent with the observation that, in the spring of 
2000, following the implementation, and then cessation, 
of losartan therapy, BP values fell progressively, and rose 
progressively, each over several days (Figure 1). However, 
when losartan was restarted in the summer of 2002, the 
fall was immediate. This hinted at an additional seasonal 
influence, conditional on losartan dosage that would be 
uncovered (“unmasked”) in later years (Figures 6, 9).
Unmasking of angiotensin II subtype 2 receptors
Treatment with ACE inhibitors lowers the circulat-
ing concentration of Ang II, so decreasing its reaction 
with the dominant AT1R subtype, and thus lowering BP. 
However, the increase in the circulating concentration 
of Ang II, following blockage of the AT1R subtype with 
losartan, should suffice to affect the losartan-insensitive, 
low abundance, AT2R subtype. Activation of AT2R usu-
ally counteracts the effects of AT1R activation (e.g. vaso-
dilation not vasoconstriction) [29, 30]. It is reported for 
Figure 8 Daily values for SBP, DBP, and losartan dosages for the year 
2011, as a function of the corresponding maximum environmental 
temperatures. Least-squares regression fits (third order polynomial) to 
the points are shown as continuous lines. This is a re-plot of the data 
of Figure 5.
Figure 9 Relationship between daily losartan requirements for the 
2003-2014 period and corresponding maximum environmental 
temperatures. The third order regressions through data points (e.g. 
Figures 7, 8) are shown for each year. Line colouring for different years 
follows that of Figure 6. Consecutive r2 values for 2011–2014 were 
0.22, 0.38, 0.34, and 0.45.
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hypertension-prone rats that Ang II will cause AT2R-
mediated vasodilation, provided AT1R is blocked and 
AT2R expression is upregulated [31, 32]. Thus, activa-
tion of AT2R is conditional, and is described as being 
“unmasked” or “trumped” when AT1R-mediated effects 
are inhibited by agents such as losartan [33–35]. Indeed, 
Abdulla and Johns [36] recently reported for rats that 
losartan increased the fall in BP following the AT2R 
receptor-associated inhibition of renal sympathetic nerve 
activity, which was part of the homeostatic response to 
total body fluid volume expansion, such as normally 
occurs in humans in summertime [37]. They concluded 
that: “The basal level of central AT2 receptor activation 
is not involved in the normal renal sympatho-inhibition 
due to volume expansion, unless the counter-regula-
tory AT1 receptors are blocked”. Thus, there is again an 
“unmasking” effect of losartan. These conclusions from 
rodents are supported by studies of Bartter and Gitelman 
syndromes (BS/GS) patients, where there is endogenous 
antagonism of AT1R signalling that in many respects 
resemble inhibition by losartan (e.g. Ang II elevation) [38, 
39].
Hypothesis
A working hypothesis, consistent with animal experi-
ments and BS/GS studies, is that under conditions 
of heat-stress (e.g. vascular dilation, salt loss), there 
is increased expression of a countervailing, losartan-
insensitive, receptor subtype (AT2R). By lowering BP in 
response to antiotensin-II, AT2R would facilitate fine-
tuning of the AT1R-mediated vasoconstriction that sup-
ports BP when superficial veins dilate to enhance body 
cooling. This AT2R activity might be sufficient to explain 
a small summertime BP dip found in normal human sub-
jects whose Ang II levels are not increased (Figure 2). The 
dip would be greatly enhanced when Ang II levels are 
increased at higher losartan dosages. Under this condi-
tion, the excess of Ang II would be expected to react with 
the AT2R, so greatly amplifying the losartan-induced fall 
in BP. To this extent, the present human study is sup-
portive of most rodent and BS/GS studies. The hypoth-
esis predicts that summertime dips would be decreased 
either by ACE inhibitors, or by AT2R antagonists, such as 
EMA401 [40]. Indeed, the study of benazepril by Chen 
et al. [15] supports the hypothesis and is in keeping with 
the recommended caution regarding combination ther-
apy with ACE inhibitors and ARBs [41]. AT2R agonists, 
including truncated Ang II fragments, are possible novel 
antihypertensive agents [34].
Night‑time dipping
ABP recordings often reveal a small dip in BP values 
when subjects are resting at night. Although carried 
out on biased groups (members of different summer 
and winter populations that had been selected to attend 
hypertension clinics), ABP studies in Italy [2, 3] found 
that, in summertime, night-time dipping was less evident 
and SBPs were slightly increased; it was only with day-
time BP measurements that the summertime decrease 
was evident. The night-time SBP increase was particu-
larly apparent in elderly subjects receiving antihyper-
tensive medication (type not specified). While noting 
that “milder sleep problems associated with hot weather 
cannot be completely excluded” [3], and that there may 
be “different sleeping behaviors between summer and 
winter” [2], the authors suggested that there is often a, 
clinic-directed or self-directed, reduction in medication 
in summertime, either because of a measured daytime 
lowering of BP, or because it is “common knowledge” that 
such lowering would have occurred [2]. Thus, those who 
would reduce the number of medications, or reduce dos-
ages (as in the present study), were cautioned by Mod-
esti et al. [3] that “the results of our study clearly indicate 
that the practice of reducing treatment in the summer 
in the elderly based on low clinic BP values is not good, 
because it might be responsible for a potentially danger-
ous increase in night BP”.
Nevertheless, given that hypertension-related adverse 
cardiovascular events are less in summer, then correct-
ing, at this time of the year, for the daytime decrease in 
SBP, may be more important that correcting for a night-
time increase. Determining the swings and roundabouts 
of this is a matter for future study, but a prudent interim 
measure might be to take some or all of whatever medi-
cations are deemed necessary in hot weather, late in 
the evening. Such a season-tailored ‘chronotherapeutic 
approach’ [12, 42] touches on the issue of the period of 
bioavailability of a medication after ingestion (as dis-
cussed above [27, 28]).
Conclusions
There should be greater awareness that the inflection 
points on J-curves [43] might vary on a seasonal basis. 
This awareness should encourage close self-monitoring 
of BP, with appropriate adjustment of medication dosage, 
especially in the case of losartan. Such dosage adjustment 
may be necessary for those living in, or travelling to, geo-
graphical regions where temperatures are seasonally or 
continually high. Assuming temperature to be primary, 
then this caveat might also apply to those engaging in 
hot activities (e.g. Turkish baths, hot yoga). More com-
prehensive softwares in BP monitoring devises might 
take into account both environmental temperatures and 
recent BP readings, and automatically recommend daily 
medication adjustment. Although randomized, dou-
ble-blind, trials, may sometimes lead to proposals for 
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increases in losartan dosages (e.g. Konstam et  al. [44] 
advise elevation from 50 to 150 mg), it would seem that 
the climate of the country where such trials had taken 
place should be considered when assessing the risk-ben-
efits of such regimens. Indeed, hypertension has been 
invoked as a factor explaining higher mortality in cold 
climates [45]. Sadly, studies of ARB-induced hypotension 
and AKI, both in the elderly [46], and in diabetic patients 
[47], give little weight to seasonal factors and dosage vari-
ation. An association of medication-induced hypoten-
sion with cognitive impairment in the elderly has led to 
disparagement of “one size fits all” approaches to therapy 
[48]. Finally, as noted by Verberk et al. [49] there may be 
direct economic benefits to health care systems if exces-
sive dosages of costly medications are avoided.
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